We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Abacavir has no prothrombotic effect on platelets in vitro.
- Authors
Diallo, Yacouba L.; Ollivier, Véronique; Joly, Véronique; Faille, Dorothée; Catalano, Giovanna; Jandrot-Perrus, Martine; Rauch, Antoine; Yeni, Patrick; Ajzenberg, Nadine
- Abstract
<bold>Objectives: </bold>HIV patients exposed to abacavir have an increased risk of myocardial infarction, with contradictory results in the literature. The aim of our study was to determine whether abacavir has a direct effect on platelet activation and aggregation using platelets from healthy donors and from HIV-infected patients under therapy with an undetectable viral load.<bold>Methods: </bold>Platelet-rich plasma (PRP) or whole blood from healthy donors was treated with abacavir (5 or 10 μg/mL) or its active metabolite carbovir diphosphate. Experiments were also performed using blood of HIV-infected patients (n = 10) with an undetectable viral load. Platelet aggregation was performed on PRP by turbidimetry and under high shear conditions at 4000 s-1. Platelet procoagulant potential was analysed by measuring thrombin generation by thrombinography.<bold>Results: </bold>Abacavir and carbovir diphosphate significantly increased the aggregation of platelets from healthy donors induced by collagen at 2 μg/mL (P = 0.002), but not at 0.5 μg/mL. No effect of abacavir or carbovir diphosphate was observed on platelet aggregation induced by other physiological agonists or by high shear stress, or on thrombin generation. Pretreatment of blood from HIV-infected patients with abacavir produced similar results.<bold>Conclusions: </bold>Our results suggest that abacavir does not significantly influence platelet activation in vitro when incubated with platelets from healthy donors or from HIV-infected patients. It is, however, not excluded that a synergistic effect with other drugs could promote platelet activation and thereby play a role in the pathogenesis of myocardial infarction.
- Subjects
ABACAVIR; BLOOD platelets; IN vitro studies; DIAGNOSIS of HIV infections; HIV infection risk factors; MYOCARDIAL infarction risk factors; BLOOD platelet activation; BLOOD platelet aggregation; THROMBIN; ANTI-HIV agents; REVERSE transcriptase inhibitors; DEOXYRIBONUCLEOSIDES
- Publication
Journal of Antimicrobial Chemotherapy (JAC), 2016, Vol 71, Issue 12, p3506
- ISSN
0305-7453
- Publication type
journal article
- DOI
10.1093/jac/dkw303